Menu


- Home
- Expertise
- What we do
- What we have
- Who we are
- Resource Library
AIM: This study was undertaken to increase understanding of the utilization of a newly introduced statin through evaluation of characteristics of ‘real-life’ patients in a pharmacoepidemiology program in the USA, the Netherlands, the UK and Canada.METHODS: This was an observational analysis of prospectively collected data from primary care patients classified as new users of rosuvastatin or any other statin
BACKGROUND: Statins (inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase) are associated with rare but serious adverse events involving the muscle, kidney and liver. To compare the safety profile of rosuvastatin with other marketed statins, foupharmacoepidemiological studies were conducted using different national healthcare databases
The overall objective of the EU-ADR project is the design, development, and validation of a computerised system that exploits data from electronic health records and biomedical databases for the early detection of adverse drug reactions. Eight diffrent databases, containing health records of more than 30 million European citizens, are involved in the project
The overall objective of the eu-ADR project is the design, development, and validation of a computerised system that exploits data from electronic health records and biomedical databases for the early detection of adverse drug reactions. Eight diffrent databases, containing health records of more than 30 million European citizens, are involved in the project
Results from clinical trials and clinical practice have shown statins to be generally well tolerated with a low frequency of clinically relevant side effects. Nevertheless, there are rare occasions when adverse events (AEs), sometimes serious, mayccur. Rosuvastatin is the newest statin to be approved in the USA and many other countries